Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.

Zeiner PS, Kinzig M, Divé I, Maurer GD, Filipski K, Harter PN, Senft C, Bähr O, Hattingen E, Steinbach JP, Sörgel F, Voss M, Steidl E, Ronellenfitsch MW.

J Clin Med. 2019 Nov 21;8(12). pii: E2031. doi: 10.3390/jcm8122031.

2.

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.

Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, Rizzato S, Bellu L, Pambuku A, Farina M, Magni G, Indraccolo S, Gardiman MP, Soffietti R, Zagonel V.

Lancet Oncol. 2019 Jan;20(1):110-119. doi: 10.1016/S1470-2045(18)30675-2. Epub 2018 Dec 3.

PMID:
30522967
3.

Regorafenib in patients with recurrent high-grade astrocytoma.

Kebir S, Rauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK, Pierscianek D, Stuschke M, Forsting M, Sure U, Keyvani K, Kleinschnitz C, Scheffler B, Glas M.

J Cancer Res Clin Oncol. 2019 Apr;145(4):1037-1042. doi: 10.1007/s00432-019-02868-5. Epub 2019 Feb 28.

PMID:
30820715
4.

Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer.

Osawa H.

Mol Clin Oncol. 2017 Mar;6(3):365-372. doi: 10.3892/mco.2017.1145. Epub 2017 Jan 31.

5.

GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.

Nakamizo S, Sasayama T, Shinohara M, Irino Y, Nishiumi S, Nishihara M, Tanaka H, Tanaka K, Mizukawa K, Itoh T, Taniguchi M, Hosoda K, Yoshida M, Kohmura E.

J Neurooncol. 2013 May;113(1):65-74. doi: 10.1007/s11060-013-1090-x. Epub 2013 Mar 1.

6.

FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.

Schaub C, Greschus S, Seifert M, Waha A, Blasius E, Rasch K, Landwehr C, Mack F, Schäfer N, Stuplich M, Kebir S, Vilz B, Scheffler B, Boström J, Simon M, Urbach H, Glas M, Herrlinger U.

Oncology. 2013;85(3):191-5. doi: 10.1159/000354692. Epub 2013 Sep 5.

PMID:
24008924
7.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

8.

Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.

Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H.

Am J Clin Oncol. 2017 Jun;40(3):228-234. doi: 10.1097/COC.0000000000000156.

PMID:
25436828
9.

Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.

Verburg N, Koopman T, Yaqub MM, Hoekstra OS, Lammertsma AA, Barkhof F, Pouwels PJW, Reijneveld JC, Heimans JJ, Rozemuller AJM, Bruynzeel AME, Lagerwaard F, Vandertop WP, Boellaard R, Wesseling P, de Witt Hamer PC.

Neuro Oncol. 2019 Sep 24. pii: noz180. doi: 10.1093/neuonc/noz180. [Epub ahead of print]

PMID:
31550353
10.

Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.

Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B, Smits M.

Neuro Oncol. 2017 Jun 1;19(6):853-861. doi: 10.1093/neuonc/now311.

11.

Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.

Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM.

J Neurooncol. 2017 Aug;134(1):177-188. doi: 10.1007/s11060-017-2506-9. Epub 2017 May 25.

12.

Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.

Kyritsis AP, Yung WK, Jaeckle KA, Bruner J, Gleason MJ, Ictech SE, Flowers A, Levin VA.

Neurosurgery. 1996 Nov;39(5):921-6.

PMID:
8905746
13.

Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.

Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, Sabel M, Langen KJ.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):22-33. doi: 10.1007/s00259-012-2251-4. Epub 2012 Sep 29.

PMID:
23053325
14.

Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.

Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, Norden AD.

J Neurooncol. 2013 Nov;115(2):267-76. doi: 10.1007/s11060-013-1225-0. Epub 2013 Aug 22.

PMID:
23974656
15.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
16.

18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.

Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM.

J Neurooncol. 2018 Sep;139(2):399-409. doi: 10.1007/s11060-018-2877-6. Epub 2018 Apr 20.

17.

Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI.

Bosnyák E, Kamson DO, Robinette NL, Barger GR, Mittal S, Juhász C.

J Neurooncol. 2016 Jan;126(2):317-25. doi: 10.1007/s11060-015-1970-3. Epub 2015 Oct 29.

18.

To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.

Paľa A, Coburger J, Scherer M, Ahmeti H, Roder C, Gessler F, Jungk C, Scheuerle A, Senft C, Tatagiba M, Synowitz M, Wirtz CR, Schmitz B, Unterberg AW.

J Neurosurg. 2019 Jul 19:1-8. doi: 10.3171/2019.4.JNS183395. [Epub ahead of print]

PMID:
31323633
19.

Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.

Galldiks N, Dunkl V, Ceccon G, Tscherpel C, Stoffels G, Law I, Henriksen OM, Muhic A, Poulsen HS, Steger J, Bauer EK, Lohmann P, Schmidt M, Shah NJ, Fink GR, Langen KJ.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2377-2386. doi: 10.1007/s00259-018-4082-4. Epub 2018 Jul 7.

PMID:
29982845
20.

Progressive Low-Grade Glioma: Assessment of Prognostic Importance of Histologic Reassessment and MRI Findings.

Narang AK, Chaichana KL, Weingart JD, Redmond KJ, Lim M, Olivi A, Quinones-Hinojosa A, Kleinberg LR.

World Neurosurg. 2017 Mar;99:751-757. doi: 10.1016/j.wneu.2016.04.030. Epub 2016 Apr 19.

PMID:
27108796

Supplemental Content

Support Center